EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Investigating the Binding Mode of a Naphthol‐Based Inhibitor Targeting SARS‐CoV‐2 Main Protease

Ifigeneia Akrani iD, Haifa El Kilani, Franck Touret iD, Sophia Kouvali, Veronika Gourni, Aggeliki Tsoka, Joulia K Tsetis, Constantinos Vorgias, Rolf Hilgenfeld, Ioannis K Kostakis iD, Vassilios Myrianthopoulos iD, Emmanuel Mikros iD

ChemMedChem · 2026

DOI: 10.1002/cmdc.70448 ↗

At a glance

Journal article in ChemMedChem, 2026. Written by Ifigeneia Akrani and 11 co-authors. Institution: Department of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece. Major MEDLINE topics: SARS-CoV-2, Antiviral Agents, Naphthols, Coronavirus 3C Proteases. 61 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: HORIZON-MSCA-2022-SE-01 "GreenCosmIn" Project, "KLEON TSETIS Non-Profit Civil Company (NPCC) for Scientific Research and Culture" (KLEON TSETIS Foundation).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Regardless of the massive global efforts to combat the virus causing SARS‐CoV‐2 syndrome, the infection remains a substantial health challenge worldwide in the years following 2019. To this direction, targeting the main viral protease M pro has been proposed as a tractable and particularly promising approach toward developing effective and safe COVID‐19 antivirals. By applying an integrated workflow combining a previously developed in silico consensus ranking protocol with two orthogonal in vitro methods, the NCI/DTP repository is screened and the discovery of an original naphthol scaffold with M pro inhibitory properties is reported. The hit is characterized in terms of structure and binding thermodynamics by combining X‐ray crystallography and isothermal titration calorimetry where a binding affinity constant of 1.55 μM is determined. The compound is further evaluated against virus‐infected cells, where an EC 50 value of 7.23 μM and comparable toxicity with nirmatrelvir are measured. Chemical synthesis is additionally employed to facilitate optimal exploration of the structure–activity relationship landscape regarding the new hit. By integrating computational, biophysical, and enzymatic methods, the suggested approach allows the combination of a structural hypothesis with functional evidence and shows its capacity toward identifying and rationally optimizing structurally original noncovalent M pro inhibitors.

Subjects

MeSH terms (MEDLINE)

SARS-CoV-2Antiviral AgentsNaphtholsCoronavirus 3C ProteasesProtease InhibitorsViral Nonstructural ProteinsBetacoronavirusHumansStructure-Activity RelationshipCrystallography, X-RayThermodynamicsProtein BindingBinding SitesAnimals

Author keywords

antiviral agentsbiophysicsconsensus screeningmolecular simulationsnaphthols

Substances

Antiviral AgentsNaphtholsCoronavirus 3C ProteasesProtease InhibitorsViral Nonstructural Proteins3C-like proteinase, SARS-CoV-2

Authors and institutions

  • Department of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece.
  • Institute of Molecular Medicine, University of Lübeck, Lübeck, Germany.
  • Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, Institution IRD 190, Inserm 1207, RBA), Marseille, France.
  • Department of Biology, National and Kapodistrian University of Athens, Athens, Greece.
  • Uni-Pharma S.A., Athens, Greece.
  • Pharma-Informatics Unit, Athena Research and Innovation Center in Information Communication and Knowledge Technologies, Marousi, Greece.

ORCID profiles: Ifigeneia Akrani, Franck Touret, Ioannis K Kostakis, Vassilios Myrianthopoulos, Emmanuel Mikros

Funding

  • HORIZON-MSCA-2022-SE-01 "GreenCosmIn" Project
  • "KLEON TSETIS Non-Profit Civil Company (NPCC) for Scientific Research and Culture" (KLEON TSETIS Foundation)

Cite

APA

Akrani, I., El Kilani, H., Touret, F., Kouvali, S., Gourni, V., Tsoka, A., Tsetis, J. K., Vorgias, C., Hilgenfeld, R., Kostakis, I. K., Myrianthopoulos, V., & Mikros, E. (2026). Investigating the Binding Mode of a Naphthol‐Based Inhibitor Targeting SARS‐CoV‐2 Main Protease. ChemMedChem. https://doi.org/10.1002/cmdc.70448

Vancouver

Akrani I, El Kilani H, Touret F, Kouvali S, Gourni V, Tsoka A, et al. Investigating the Binding Mode of a Naphthol‐Based Inhibitor Targeting SARS‐CoV‐2 Main Protease. ChemMedChem. 2026. doi:10.1002/cmdc.70448

BibTeX
@article{Akrani2026,
  author = {Akrani, Ifigeneia and El Kilani, Haifa and Touret, Franck and Kouvali, Sophia and Gourni, Veronika and Tsoka, Aggeliki and Tsetis, Joulia K and Vorgias, Constantinos and Hilgenfeld, Rolf and Kostakis, Ioannis K and Myrianthopoulos, Vassilios and Mikros, Emmanuel},
  title = {Investigating the Binding Mode of a Naphthol‐Based Inhibitor Targeting SARS‐CoV‐2 Main Protease},
  journal = {ChemMedChem},
  year = {2026},
  doi = {10.1002/cmdc.70448}
}
Start for free →